Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,758Revenue (TTM) $M871Net Margin (%)1.2Altman Z-Score-0.2
Enterprise Value $M3,083EPS (TTM) $0.0Operating Margin %-3.8Piotroski F-Score6
P/E(ttm)87.1Beneish M-Score-3.2Pre-tax Margin (%)-13.7Higher ROA y-yY
Price/Book0.510-y EBITDA Growth Rate %--Quick Ratio0.6Cash flow > EarningsY
Price/Sales0.95-y EBITDA Growth Rate %--Current Ratio0.6Lower Leverage y-yN
Price/Free Cash Flow335y-y EBITDA Growth Rate %--ROA % (ttm)0.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)0.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M555ROIC % (ttm)0.1Gross Margin Increase y-yY

Gurus Latest Trades with NYSE:BTE

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

NYSE:BTE is held by these investors:

NYSE:BTE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bowzer, James LeeSenior Officer 2014-12-11Buy5,000$14.15-76.89view
Ector, Brian GordonSenior Officer 2014-12-11Buy1,100$16.24-79.86view
Ector, Brian GordonSenior Officer 2014-12-11Buy1,950$16.19-79.8view
Ector, Brian GordonSenior Officer 2014-12-11Buy1,950$16.18-79.79view
Verm, Michael LloydSenior Officer 2014-12-11Buy5,000$13.62-75.99view
Hercus, CameronSenior Officer 2014-11-24Buy1,000$30.5-89.28view
Brussa, John AlbertDirector 2014-11-04Buy5,000$32.95-90.08view
Verm, Michael LloydSenior Officer 2014-10-07Buy1,000$36.27-90.98view
Verm, Michael LloydSenior Officer 2014-10-07Buy1,000$35.69-90.84view
Verm, Michael LloydSenior Officer 2014-09-18Buy2,000$39.42-91.7view

Quarterly/Annual Reports about NYSE:BTE:

    News about NYSE:BTE:

    Articles On GuruFocus.com
    Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presen Jun 23 2018 
    Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presen Jun 23 2018 
    New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potenti Jun 23 2018 
    ADT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ADT Inc. - AD Jun 23 2018 
    One Third of Participants in a Workforce Study Reduce Risk for Diabetes after Employer Wellness Scre Jun 23 2018 
    Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and establishe Jun 23 2018 
    Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at Jun 23 2018 
    MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scient Jun 23 2018 
    Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the Am Jun 23 2018 
    Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients wit Jun 23 2018 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat